Radezolid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Radezolid
Accession Number
DB12339
Description

Radezolid has been used in trials studying the treatment of Abscess, Bacterial Skin Diseases, Streptococcal Infections, Infectious Skin Diseases, and Staphylococcal Skin Infections, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 438.463
Monoisotopic: 438.181566788
Chemical Formula
C22H23FN6O3
Synonyms
Not Available
External IDs
  • AND RX-01_667
  • RX-013
  • RX-103
  • RX-1741

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
URibosome-binding protein 1Not AvailableHumans
U60S ribosome subunit biogenesis protein NIP7 homologNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Radezolid is combined with Acenocoumarol.
DicoumarolThe risk or severity of bleeding can be increased when Radezolid is combined with Dicoumarol.
FluindioneThe risk or severity of bleeding can be increased when Radezolid is combined with Fluindione.
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Radezolid.
PhenindioneThe risk or severity of bleeding can be increased when Radezolid is combined with Phenindione.
PhenprocoumonThe risk or severity of bleeding can be increased when Radezolid is combined with Phenprocoumon.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Radezolid.
Typhoid vaccineThe therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Radezolid.
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Radezolid.
WarfarinThe risk or severity of bleeding can be increased when Radezolid is combined with Warfarin.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Radezolid hydrochloride37CW568NXL869884-77-5UQKABVKLBIJYBI-FYZYNONXSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenylmethylamines / Benzylamines / Aralkylamines / Fluorobenzenes / Aryl fluorides / Oxazolidinones / Triazoles / Carbamate esters / Heteroaromatic compounds / Dialkylamines
show 8 more
Substituents
1,2,3-triazole / Amine / Aralkylamine / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Azole / Benzylamine / Biphenyl
show 24 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
53PC6LO35W
CAS number
869884-78-6
InChI Key
BTTNOGHPGJANSW-IBGZPJMESA-N
InChI
InChI=1S/C22H23FN6O3/c1-14(30)25-12-19-13-29(22(31)32-19)18-6-7-20(21(23)8-18)16-4-2-15(3-5-16)9-24-10-17-11-26-28-27-17/h2-8,11,19,24H,9-10,12-13H2,1H3,(H,25,30)(H,26,27,28)/t19-/m0/s1
IUPAC Name
N-{[(5S)-3-[2-fluoro-4'-({[(1H-1,2,3-triazol-5-yl)methyl]amino}methyl)-[1,1'-biphenyl]-4-yl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
SMILES
CC(=O)NC[[email protected]]1CN(C(=O)O1)C1=CC=C(C(F)=C1)C1=CC=C(CNCC2=CN=NN2)C=C1

References

General References
Not Available
PubChem Compound
11224409
PubChem Substance
347828598
ChemSpider
9399462
ChEMBL
CHEMBL455461
ZINC
ZINC000040379938
PDBe Ligand
RD8
Wikipedia
Radezolid
PDB Entries
6wqq

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAbscesses / Bacterial Skin Diseases / Infectious Skin Diseases / Staphylococcal Skin Infections / Streptococcal Infections1
2CompletedTreatmentCommunity Acquired Pneumonia (CAP)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.043 mg/mLALOGPS
logP1.23ALOGPS
logP1.29ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)8.56ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area112.24 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity115.89 m3·mol-1ChemAxon
Polarizability45.19 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
Acts as a ribosome receptor and mediates interaction between the ribosome and the endoplasmic reticulum membrane.
Gene Name
RRBP1
Uniprot ID
Q9P2E9
Uniprot Name
Ribosome-binding protein 1
Molecular Weight
152471.765 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
Required for proper 34S pre-rRNA processing and 60S ribosome subunit assembly.
Gene Name
NIP7
Uniprot ID
Q9Y221
Uniprot Name
60S ribosome subunit biogenesis protein NIP7 homolog
Molecular Weight
20462.485 Da

Drug created on October 20, 2016 16:00 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates